Amendment to Research, Development and License Agreement



 EXHIBIT 10.41 
  
 Portions of this exhibit were omitted and filed separately with the Secretary of the Commission pursuant to an application for confidential treatment filed with the
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. Such portions are marked by a series of asterisks. 
  
 December 18, 2003 
  
 BY FAX and FEDERAL EXPRESS 
  
 Novo Nordisk A/S 
 Novo Allé 
 2880 Bagsvaerd 
 Denmark 
  
     Attention: Vice President, Business Development 
     Fax: 011-45-4442-1830 
  

	Re:	Research, Development and License Agreement 


	 	Between Neose Technologies, Inc. and Novo Nordisk A/S 


	 	dated as of November 17, 2003 (the “Agreement”) 


	 	(relating to ******) 

  
 Ladies and Gentlemen: 
  
 The purpose of this letter is to amend the Agreement in certain respects to reflect our recent discussions. Capitalized terms used and not otherwise defined in this
letter are used as defined in the Agreement. 
  
 1. Section 3.2.1
of the Agreement is hereby amended and restated in its entirety as follows: 
  
 ****** upon the ****** to occur of: (i) the first date on which there shall be a candidate which has been shown to meet the ****** Product, and Neose shall have delivered to Novo ****** for the production of such
candidate; and (ii) the ****** anniversary of the Effective Date. 
  
 2. Section 3.3.1 of the Agreement is hereby amended and restated in its entirety as follows: 







 Novo Nordisk A/S 
 Novo Nordisk Health Care AS 
 December 18, 2003 
 Page 2 
  
 ****** upon the ****** to occur of: (i) the first date on which there shall be a candidate which has been shown to meet the
****** Product, and Neose shall have delivered to Novo ****** for the production of such candidate; and (ii) the ****** anniversary of the Effective Date. 
  
 2. Section 5.1.1 of the Agreement is hereby amended and restated in its entirety as follows: 
  
 Exclusive License. As of the Effective Date, Neose hereby grants, and
agrees to grant, to Novo an exclusive (even as to Neose), royalty-bearing license in the Field of Use under the Neose Technology used or required to be used in the Field of Use during the Term, (i) to conduct research, sample, develop (including
clinical development), manufacture, make, use, market, promote, sell, offer for sale, have sold, distribute, import and export New Products in the Territory, and (ii) to use the Reagents in the Territory solely for the purpose of making New
Products. Such license does not permit Novo (x) to practice or use the Neose Technology outside the Field of Use or (y) to sublicense any of its rights without the prior written approval of Neose, except as provided in Section 5.1.2.

  
 3. Exhibit 1.24 to the Agreement is hereby amended and
restated as set forth in Attachment A to this letter agreement. 
  
 This letter
amends the Agreement only as herein set forth and in all other respects the Agreement is ratified and confirmed. Three originals of this letter amendment are enclosed in our Federal Express package, each of which has been executed on behalf of
Neose. Please indicate the agreement of Novo with the terms of this letter by having each company executed this letter in the space provided below, and return one fully executed copy to Neose by fax (215-315-9100) and Federal Express or DHL courier
(each to the attention of our General Counsel). 
  
 Sincerely yours, 
  
 NEOSE TECHNOLOGIES,
INC. 
  

			
	 By:
	 	 /s/ George J. Vergis


	 Name:
	 	 George J. Vergis, Ph.D.

	 Title:
	 	 Senior Vice President, Business and Commercial Development









 Novo Nordisk A/S 
 Novo Nordisk Health Care AS 
 December 18, 2003 
 Page 3 
  
 Accepted and agreed: 
  
 NOVO NORDISK A/S 
  

			
	 By:
	 	 /s/ Pierre Honore


	 Name:
	 	 Pierre Honore

	 Title:
	 	 VP Scientific Licensing

		
	 Cc:
	 	 Novo Nordisk A/S

	 	 	 Attention: General Counsel

	 	 	 Fax: 011-45-4498-0670









 ATTACHMENT A TO LETTER AMENDMENT DATED DECEMBER 18, 2003 
  

			
	 Confidential Information – Neose Technologies, Inc.
	  	EXHIBIT 1.25

  
 NEOSE PATENTS AS
OF THE DATE OF THIS AGREEMENT 
  

															
	 ******

	  	 	  	 	  	 	 	 	 	 	 	 	 	 
	 Country

	  	Case Type

	  	Status

	  	Application Number

	 	Filing Date

	 	Patent Number

	 	Issue Date

	 	Expiration Date


	 ******
	  	PCT	  	Granted	  	******	 	******	 	******	 	******	 	******
	 ******
	  	DIV	  	Pending	  	******	 	******	 	 	 	 	 	 
	 ******
	  	PCT	  	Pending	  	******	 	******	 	 	 	 	 	 
	 ******
	  	PCT	  	Published	  	******	 	******	 	 	 	 	 	 
	 ******
	  	PCT	  	Pending	  	******	 	******	 	 	 	 	 	 
	 ******
	  	PCT	  	Published	  	******	 	******	 	 	 	 	 	 
	 ******
	  	PCT	  	Pending	  	******	 	******	 	 	 	 	 	 
	 ******
	  	PCT	  	Granted	  	******	 	******	 	******	 	******	 	******
	 ******
	  	ORD	  	Pending	  	******	 	******	 	******	 	 	 	 
	 ******
	  	CON	  	Pending	  	******	 	******	 	 	 	 	 	 
	 ******
	  	CON	  	Published	  	******	 	******	 	 	 	 	 	 
	 ******
	  	DIV	  	Published	  	******	 	******	 	 	 	 	 	 
	 ******
	  	CON	  	Pending	  	******	 	******	 	 	 	 	 	 
	 ******
	  	PRO	  	Expired	  	******	 	******	 	 	 	 	 	 
	 ******
	  	RCE	  	Granted	  	******	 	******	 	******	 	******	 	******
								
	 ******

	  	 	  	 	  	 	 	 	 	 	 	 	 	 
	 Country

	  	Case Type

	  	Status

	  	Application Number

	 	Filing Date

	 	Patent Number

	 	Issue Date

	 	Expiration Date


	******	  	ORD	  	Published	  	******	 	******	 	******	 	 	 	 
	******	  	PRO	  	Expired	  	******	 	******	 	 	 	 	 	******
	******	  	PRO	  	Expired	  	******	 	******	 	 	 	 	 	******
	******	  	PRO	  	Expired	  	******	 	******	 	 	 	 	 	******
	******	  	PRO	  	Expired	  	******	 	******	 	 	 	 	 	******
								
	 ******

	  	 	  	 	  	 	 	 	 	 	 	 	 	 
	 Country

	  	Case Type

	  	Status

	  	Application Number

	 	Filing Date

	 	Patent Number

	 	Issue Date

	 	Expiration Date


	******	  	CIP	  	Pending	  	******	 	******	 	 	 	 	 	 
								
	 ******

	  	 	  	 	  	 	 	 	 	 	 	 	 	 
	 Country

	  	Case Type

	  	Status

	  	Application Number

	 	Filing Date

	 	Patent Number

	 	Issue Date

	 	Expiration Date


	 ******
	  	CON	  	Pending	  	******	 	******	 	 	 	 	 	 








 ATTACHMENT A TO LETTER AMENDMENT DATED DECEMBER 18, 2003 
  

			
	 Confidential Information – Neose Technologies, Inc.
	  	EXHIBIT 1.25

  

															
	 ******

	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 Country

	  	 Case Type

	  	 Status

	  	 Application Number

	  	 Filing Date

	  	 Patent Number

	  	 Issue Date

	  	 Expiration Date


	 ******
	  	CIP	  	Pending	  	******	  	******	  	 	  	 	  	 
								
	 ******

	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 Country

	  	 Case Type

	  	 Status

	  	 Application Number

	  	 Filing Date

	  	 Patent Number

	  	 Issue Date

	  	 Expiration Date


	 ******
	  	CIP	  	Pending	  	******	  	******	  	 	  	 	  	 
								
	 ******

	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 Country

	  	 Case Type

	  	 Status

	  	 Application Number

	  	 Filing Date

	  	 Patent Number

	  	 Issue Date

	  	 Expiration Date


	 ******
	  	CIP	  	Pending	  	******	  	******	  	 	  	 	  	 
								
	 ******

	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 Country

	  	 Case Type

	  	 Status

	  	 Application Number

	  	 Filing Date

	  	 Patent Number

	  	 Issue Date

	  	 Expiration Date


	 ******
	  	PCT	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	PCT	  	Published	  	******	  	******	  	 	  	 	  	 
	 ******
	  	ORD	  	Published	  	******	  	******	  	******	  	 	  	 
	 ******
	  	CIP	  	Granted	  	******	  	******	  	******	  	******	  	******

  







 ATTACHMENT A TO LETTER AMENDMENT DATED DECEMBER 18, 2003 
  

			
	 Confidential Information – Neose Technologies, Inc.
	  	EXHIBIT 1.25

  

															
	 ******

	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 Country

	  	 Case Type

	  	 Status

	  	 Application Number

	  	 Filing Date

	  	 Patent Number

	  	 Issue Date

	  	 Expiration Date


	 ******
	  	PCT	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	PCT	  	Granted	  	******	  	******	  	******	  	******	  	 
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	PCT	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	PCT	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	PCT	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	ORD	  	Published	  	******	  	******	  	******	  	 	  	 
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	ORD	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	CON	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	DIV	  	Granted	  	******	  	******	  	******	  	******	  	******








 ATTACHMENT A TO LETTER AMENDMENT DATED DECEMBER 18, 2003 
  

			
	 Confidential Information – Neose Technologies, Inc.
	  	EXHIBIT 1.25

  
 PROVISIONAL: The Parties
acknowledge that the following may be included by amendment. 
  

																	
	 ******

	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 Country

	  	 Sub Case

	  	 Case Type

	  	 Status

	  	 Application Number

	  	 Filing Date

	  	 Patent Number

	  	 Issue Date

	  	 Expiration Date


	******	  	 	  	PCT	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	 	  	PCT	  	Published	  	 	  	******	  	 	  	 	  	 
	******	  	 	  	PCT	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	 	  	PCT	  	Published	  	 	  	******	  	 	  	 	  	 
	******	  	 	  	PCT	  	Published	  	 	  	******	  	 	  	 	  	 
	******	  	 	  	ORD	  	Published	  	******	  	******	  	******	  	 	  	 
	******	  	 	  	CIP	  	Allowed	  	******	  	******	  	 	  	 	  	 
	******	  	D1	  	DIV	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	D2	  	DIV	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	D3	  	DIV	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	D4	  	DIV	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	D5	  	DIV	  	Published	  	******	  	******